14 results about "In vitro stimulation" patented technology

This invention discloses a veterinary aluminum hydroxide adjuvant for foot-and-mouth disease (FMD) vaccines and its preparation method via aluminum alkoxide hydrolysis. The adjuvant is a boehmite phase, and through innovative processing, the crystallinity and morphology are synergistically controlled, achieving a relative crystallinity of 10%-25%. The primary particles are rod-shaped or needle-shaped, with an average aspect ratio of 4:1 to 8:1. The preparation method includes: dissolving an aluminum alkoxide compound, then subjecting it to a controlled hydrolysis reaction at 50-80℃ and pH 4.5-6.5 under normal pressure for 36 hours, followed by aging at 425℃ for 2472 hours. The product is obtained after solid-liquid separation, washing, and drying. The obtained adjuvant exhibits an adsorption rate of over 96% for FMD virus inactivated antigen within 1 hour, and a cumulative antigen dissociation rate of less than 5% after 7 days at 37℃. In vitro stimulation of macrophages to secrete IL-1β and TNF-α levels is more than 1.7 times that of commercially available aluminum hydroxide adjuvants, significantly superior to traditional aluminum hydroxide adjuvants, providing a new material for the preparation of highly effective FMD vaccines.

The invention discloses a Brucella bacterium capable of generating a lipoid A vaccine adjuvant and an application of the Brucella bacterium. According to the invention, recombinant plasmids for expressing BacA and LpxL genes are constructed, and are transformed into Brucella through electric shock, so that a double-gene knockout strain is successfully obtained. By knocking out BacA, an ultra-long fatty acid chain of lipoid A is shortened, an organism is induced to generate an inflammatory reaction, and by knocking out LpxL, the inflammatory reaction is reduced, so that the effect of the immunologic adjuvant is achieved. LPS is extracted for in-vitro stimulation analysis, and it is found that the inflammatory response of double-gene deletion is reduced compared with that of single-gene deletion. Animal experiments show that double-gene deletion can induce an organism to generate good immune response and induce relatively high cellular immunity and humoral immunity, and a new thought is provided for research and development of gram-negative bacterium inactivated vaccines.

Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.

The invention discloses a method for in-vitro broad-spectrum stimulation of immune checkpoint up-regulation and application, the method comprises the following steps: placing a Jurkat cell line in an RPMI-1640 culture medium containing 10% of fetal calf serum and 1% of penicillin-streptomycin, carrying out in-vitro stimulation for 24-72 hours by adopting PHA with a concentration of 0.1-5 [mu] g / mL under the conditions of 37 DEG C and 5% of CO2, activating NF-kB and / or MAPK signal channels, and carrying out in-vitro broad-spectrum stimulation of immune checkpoint up-regulation. The broad-spectrum up-regulation of co-stimulatory immune checkpoints of CD28, CD40L, ICOS and the like and co-inhibitory immune checkpoints of PD-1, LAG-3, CTLA-4 and the like is realized, and the high expression state can be maintained for at least 72 hours after the PHA is removed. The invention also discloses the in-vitro broad-spectrum immune checkpoint positive T cell model constructed by the method, and the up-regulation of immune checkpoints in the model is accompanied by the increase of dose-dependent secretion of various cytokines. The model can replace a traditional model, is applied to toxicology and pharmacology research of immune checkpoint antagonists and combined synergistic effect and immune checkpoint regulation and control mechanism research, is simple and convenient to operate and high in repeatability, and provides an efficient tool for research and development of related drugs.

The present application relates to a multi-channel extracorporeal stimulator and a control method thereof. The multi-channel extracorporeal stimulator comprises a power module, a controller module, a stimulation module and a program control module. The power module is electrically connected with the controller module and the stimulation module respectively, and supplies power to the controller module and the stimulation module respectively. The program control module is in communication connection with the controller module, and sends preset program control parameter information to the controller module. The controller module is electrically connected with the stimulation module, and generates a power control signal and a stimulation program signal according to the received preset program control parameter information, sends the power control signal to the power module, and sends the stimulation program signal to the stimulation module. The stimulation module generates stimulation waveforms of multiple channels according to the received stimulation program signal. The extracorporeal stimulator and the method can realize more stimulation modes and wider stimulation current amplitude by supporting more stimulation channels, so as to set multiple treatment schemes and achieve the best treatment effect.

Provided herein are methods of producing a plurality of T cells which has been ex vivo stimulated and expanded to enrich for antigen-specific T cells. This plurality of T cells can be used to provide highly specific and efficacious T cell therapies for treatment of cancers and other conditions.

This invention discloses an electromagnetic modulation method for improving the formation of glial scars around implanted electrodes. The method selects at least two electrode channels in an implanted brain-computer interface electrode array as stimulation channels and connects them to an external stimulation driving circuit. By outputting a charge-balanced low-frequency pulse stimulation current, it implements staged modulation of the local tissue around the electrodes at different stages after implantation. Simultaneously, it continuously monitors the electrode-tissue interface impedance and / or the signal-to-noise ratio of neural signals, and performs closed-loop switching between different stimulation parameters based on the monitoring results. This method is drug-free and can utilize bipolar or tripolar current-guided stimulation configurations to regulate the spatial distribution of the local electric field. Combined with the accompanying near-field electromagnetic effect, it provides electromagnetic parameter-dependent long-term modulation of the inflammatory response of microglia and astrocytes at the implantation interface, thereby improving the long-term electrical stability of the implantation interface and extending the lifespan of the implanted electrodes.

The application belongs to the field of medical biotechnology, and particularly relates to a method for in-vitro ADP stimulation determination of platelet activation and application. The method provided by the application comprises: S1, adding buffer solution, ADP solution and anticoagulant whole blood sample into a homologous control tube and a to-be-detected tube respectively; S2, placing the homologous control tube and the to-be-detected tube at 18-28 DEG C for 5-30 min for stimulation; the final concentration of the ADP solution in the step S1 is 5-160 micromol / L; and the addition amount of the anticoagulant whole blood sample is 5-10 microliters. The method provided by the application is more direct and simple to operate, and only needs to be completed at normal temperature. After the stimulation is completed, the antibody reagent is directly added without the need of taking a flow tube for secondary dispensing and adding the antibody reagent. In addition, the sample amount of the method provided by the application is significantly reduced, the burden of patients is reduced, the ADP amount is greatly reduced, the reagent amount is saved, the collection time is significantly shortened, and the detection efficiency is greatly improved.

The invention belongs to the technical field of medicaments related to cancer immunotherapy, relates to peptides, proteins, nucleic acids and cells for immunotherapy, and particularly relates to antigenic peptides and peptide compositions for triple negative breast cancer immunotherapy. In particular to a polypeptide which is selected from polypeptides with sequences as shown in SEQ ID NO: 1 to SEQ ID NO: 89. Or a variant sequence thereof. The invention also relates to independent use of the main component of the polypeptide vaccine or combined use of the main component of the polypeptide vaccine and other tumor-related drug active components for stimulating anti-tumor immune response or stimulating DC cells, T cells or vaccine compounds in vitro. Peptides bound to the major histocompatibility complex (MHC), or peptides as such, can be used as antibodies to recognize soluble T cell receptors and other binding molecular targets.

This invention relates to the field of medical device technology and discloses an external vibration-electric stimulation device for erectile dysfunction (ED), comprising a shell, a fixing chamber fixedly connected to the top of the shell, a flexible heating layer fixedly connected to the inner diameter of the shell, multiple vibration motors fixedly connected inside the flexible heating layer, multiple ultrasonic transducers fixedly connected inside the flexible heating layer, a shape memory alloy support frame disposed within the inner diameter of the flexible heating layer, multiple micro-airbags disposed within the inner diameter of the shape memory alloy support frame, an inner bonding layer fixedly connected between the multiple micro-airbags, and an electrical stimulation electrode and a bioimpedance detection electrode disposed within the inner diameter of the inner bonding layer. By integrating multiple stimulation methods such as vibration stimulation, electrical stimulation, ultrasonic stimulation, and thermotherapy stimulation in the same external stimulation device and its corresponding method, and by having a controller uniformly schedule each stimulation component, multiple stimulation methods can be executed collaboratively in the same stimulation session.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention provides a method for detecting peripheral helper T cells expressing IL-5, IL-13 and IL-21 in peripheral blood with a non-diagnostic or therapeutic purpose, and belongs to the technical field of cell detection. The method provided by the invention fills the blank of Tph cell detection methods related to the type 2 inflammatory response. According to the method, the total Tph cells are obtained through flow type sorting, and then in-vitro stimulation is carried out to detect marker expression in the cells, so that the content of Tph cells related to the type 2 inflammatory response is obtained. According to the method for detecting the intracellular marker by firstly separating the Tph cells and then treating the Tph cells, interference on subsequent detection of the Tph cells due to change of expression of the cell surface marker caused by direct treatment of the PBMC cells can be avoided. In addition, the fluorescent dye selected by the intracellular marker has strong fluorescence, so that positive and negative cells can be better distinguished, and the detection sensitivity is high.

Provided herein are methods of producing a plurality of T cells which has been ex vivo stimulated and expanded to enrich for antigen-specific T cells. This plurality of T cells can be used to provide highly specific and efficacious T cell therapies for treatment of cancers and other conditions.

A non-contact nerve stimulation device is disclosed. The non-contact nerve stimulation device comprises: a stimulator for outputting electromagnetic waves for stimulating a first region of the brain from outside the body; and a device for aligning the stimulator to a stimulation position which is an anatomical position adjacent to the first region of the brain, wherein the electromagnetic waves output from the stimulator generate an active potential in the first region of the brain, and the potential activation of the first region of the brain can generate an active potential in a second region of the brain and thereby activate microglia.